William J Pitts

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2890413/publications.pdf

Version: 2024-02-01

53 papers	5,419 citations	236612 25 h-index	168136 53 g-index
59 all docs	59 docs citations	59 times ranked	6790 citing authors

#	Article	IF	Citations
1	An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads. Drug Discovery Today, 2021, 26, 1115-1125.	3.2	3
2	Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis. ACS Medicinal Chemistry Letters, 2020, 11, 1402-1409.	1.3	6
3	Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. Journal of Medicinal Chemistry, 2019, 62, 8973-8995.	2.9	212
4	Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis. ACS Medicinal Chemistry Letters, 2019, 10, 306-311.	1.3	11
5	Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3101-3106.	1.0	10
6	Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4908-4913.	1.0	12
7	Discovery of highly potent, selective, covalent inhibitors of JAK3. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4622-4625.	1.0	24
8	Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1). Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2470-2474.	1.0	6
9	An Efficient Scale-Up Synthesis of BMS-520, a Potent and Selective Isoxazole-Containing S1P₁ Receptor Agonist. Organic Process Research and Development, 2016, 20, 989-995.	1.3	15
10	Discovery and Structureâ€“Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P₁). Journal of Medicinal Chemistry, 2016, 59, 6248-6264.	2.9	22
11	Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P₁): Discovery and SAR of a Novel Isoxazole Based Series. Journal of Medicinal Chemistry, 2016, 59, 2820-2840.	2.9	20
12	Practical olefin hydroamination with nitroarenes. Science, 2015, 348, 886-891.	6.0	387
13	Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain. Journal of Biological Chemistry, 2015, 290, 11061-11074.	1.6	90
14	Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 845-849.	1.3	11
15	Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5721-5726.	1.0	27
16	Toolkit of reagents to aid drug discovery. Nature, 2012, 492, 45-46.	13.7	2
17	Novel tricyclic inhibitors of IKK2: Discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066). Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7006-7012.	1.0	9
18	Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: Synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 383-386.	1.0	11

#	Article	IF	Citations
19	One-Pot Synthesis of Azaindoles via Palladium-Catalyzed Î±-Heteroarylation of Ketone Enolates. Journal of Organic Chemistry, 2010, 75, 5316-5319.	1.7	36
20	Periodic, Partial Inhibition of IÎºB Kinase Î²-Mediated Signaling Yields Therapeutic Benefit in Preclinical Models of Rheumatoid Arthritis. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 349-360.	1.3	26
21	Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1935-1938.	1.0	20
22	Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IÎºB kinase. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2646-2649.	1.0	19
23	Novel Tricyclic Inhibitors of IÎºB Kinase. Journal of Medicinal Chemistry, 2009, 52, 1994-2005.	2.9	25
24	Chapter 12 Advances in the Discovery of Small Molecule JAK3 Inhibitors. Annual Reports in Medicinal Chemistry, 2009, 44, 247-264.	0.5	14
25	Advances in the Discovery of IÎºB Kinase Inhibitors. Annual Reports in Medicinal Chemistry, 2008, 43, 155-170.	0.5	8
26	Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-Î± converting enzyme (TACE). Bioorganic and Medicinal Chemistry Letters, 2007, 17, 266-271.	1.0	55
27	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1101-1106.	1.0	91
28	Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structureâ€“activity relationships. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1829-1833.	1.0	35
29	Structure-Based Design of Potent and Selective Inhibitors of Collagenase-3 (MMP-13).. ChemInform, 2005, 36, no.	0.1	1
30	Identification of purine inhibitors of phosphodiesterase 7 (PDE7). Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2955-2958.	1.0	48
31	Novel inhibitors of IMPDH. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 543-546.	1.0	27
32	Quinolone-Based IMPDH inhibitors: introduction of basic residues on ring D and SAR of the corresponding mono, di and benzofused analogues. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 547-551.	1.0	12
33	Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl moiety. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2059-2063.	1.0	28
34	Identification of novel and potent isoquinoline aminooxazole-Based IMPDH inhibitors. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1345-1348.	1.0	27
35	Phosphodiesterase 7A-Deficient Mice Have Functional T Cells. Journal of Immunology, 2003, 171, 6414-6420.	0.4	95
36	A Modified Approach to 2-(N-Aryl)-1,3-oxazoles:â€‰ Application to the Synthesis of the IMPDH Inhibitor BMS-337197 and Analogues. Organic Letters, 2002, 4, 2091-2093.	2.4	38

#	Article	IF	Citations
37	Discovery ofN-[2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4-morpholineacetamide as a Novel and Potent Inhibitor of Inosine Monophosphate Dehydrogenase with Excellent in Vivo Activity. Journal of Medicinal Chemistry, 2002, 45, 2127-2130.	2.9	44
38	Rapid synthesis of triazine inhibitors of inosine monophosphate dehydrogenase. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2137-2140.	1.0	42
39	Novel amide-based inhibitors of inosine 5â€²-monophosphate dehydrogenase. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2879-2882.	1.0	16
40	A survey of cyclic replacements for the central diamide moiety of inhibitors of inosine monophosphate dehydrogenase. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3125-3128.	1.0	16
41	Novel diamide-Based inhibitors of IMPDH. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1323-1326.	1.0	24
42	Retinoic Acid and Vitamin E Modulate Expression and Release of CD178 in Carcinoma Cells: Consequences for Induction of Apoptosis in CD95-Sensitive Cells. Experimental Cell Research, 2001, 270, 248-258.	1.2	10
43	Isoxazolines as Potent Antagonists of the Integrin Î±vÎ²3. Journal of Medicinal Chemistry, 2000, 43, 27-40.	2.9	86
44	Terphenyl cyclooxygenase-2 (COX-2) inhibitors: Optimization of the central ring and o-biphenyl analogs. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 919-924.	1.0	25
45	Rapid synthesis of RGD mimetics with isoxazoline scaffolds on solid phase: Identification of Î±vÎ²3 antagonists lead compounds. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 937-942.	1.0	30
46	Structure-activity relationships (SAR) of some tetracyclic heterocycles related to the immunosuppressive agent brequinar sodium. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 307-312.	1.0	21
47	MEK inhibitors: The chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2839-2844.	1.0	384
48	Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase. Journal of Biological Chemistry, 1998, 273, 18623-18632.	1.6	2,764
49	The Immunosuppressive Metabolite of Leflunomide Is a Potent Inhibitor of Human Dihydroorotate Dehydrogenase. Biochemistry, 1996, 35, 1270-1273.	1.2	284
50	Chemistry and pharmacokinetics of diarylthiophenes and terphenyls as selective COX-2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 2907-2912.	1.0	41
51	Immunosuppressive structure-activity relationships of Brequinar and related cinchoninic acid derivatives. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1549-1554.	1.0	27
52	Synthesis of cycloprop[c]indol-5-ones from 4-diazo-3-[n-(2-propenyl)amido]cyclohexadien-1-ones. Exploration of copper(I) and copper(II) complexes as catalysts. Journal of Organic Chemistry, 1991, 56, 3048-3054.	1.7	79
53	Synthesis of the left-hand ring of the antitumor antibiotic CC-1065 by an intramolecular carbenoid addition route. Synthesis and reactivity of 4-diazo-4,7-dihydroindol-7-ones and related compounds. Journal of Organic Chemistry, 1988, 53, 5097-5107.	1.7	43